

Afghanistan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Afghanistan			
2. Grant Number: 1115-AFG-04c-X			
3. Date of Decision Letter: 04/11/2014			
4. Date of the Partnership Framework Agreement: 30/04/2014			
5. Programme Title: NVS, Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2009 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2009-2014	2015	Total ²
Programme Budget (US\$)	US\$61,336,271 ³	US\$5,878,000	US\$67,214,271
10. Vaccine Introduction Grant: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴

Type of supplies to be purchased with GAVI funds in each year	2009-2014	2015
Number of Pentavalent vaccines doses		2,861,000
Number of AD syringes		2,319,400
Number of re-constitution syringes		
Number of safety boxes		25,525
Annual Amounts (US\$)	US\$61,336,271 ⁵	US\$5,878,000

12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations: Reference code: 1115-AFG-04c-X-C According to the Co-Financing Policy, the Country falls within the group Low Income
The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	316,500
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$616,521
Total Co-Financing Payments (US\$) (including freight)	US\$635,500

15. Operational support for campaigns: Not applicable

⁴ This is the amount that GAVI has approved.

⁵ This is the consolidated amount for all previously approved years.

Additional documents to be delivered for future disbursements:	
Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat in the context of GAMR Internal Appraisal for support in 2016
<p>16. Financial Clarifications: The Country shall provide the following clarifications to GAVI*:</p> <p><i>*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements</i></p>	
<p>17. Other conditions: Not applicable</p>	

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes
4 November 2014

Afghanistan VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Afghanistan			
2. Grant Number: 1315-AFG-12c-X			
3. Date of Decision Letter: 04/11/2014			
4. Date of the Partnership Framework Agreement: 30/04/2014			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme Duration⁶: 2013 -2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2013-2014	2015	Total ⁷
Programme Budget (US\$)	US\$28,439,440	US\$16,500,500	US\$44,939,940
10. Vaccine Introduction Grant: Not applicable			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁸

Type of supplies to be purchased with GAVI funds in each year	2015
Number of Pneumococcal vaccines doses	3,009,600
Number of AD syringes	3,323,000
Number of re-constitution syringes	
Number of safety boxes	36,575
Annual Amounts (US\$)	US\$16,500,500

12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations: Reference code: 1315-AFG-12c-X-C According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	180,000
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$602,185
Total Co-Financing Payments (US\$) (including freight)	US\$638,000

15. Operational support for campaigns: Not applicable

⁸ This is the amount that GAVI has approved.

16. Additional documents to be delivered for future disbursements:	
Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat in the context of GAMR Internal Appraisal for support in 2016
17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: <i>*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements</i>	
18. Other conditions: Not applicable.	

Signed by,
On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes
4 November 2014